We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Rapid Test Detects Both HIV and TB in Blood Sample

By LabMedica International staff writers
Posted on 21 Nov 2023
Print article
Image: The new and rapid test detects both HIV and tuberculosis at the same time with a small amount of blood (Photo courtesy of Tulane University)
Image: The new and rapid test detects both HIV and tuberculosis at the same time with a small amount of blood (Photo courtesy of Tulane University)

HIV and tuberculosis (TB) frequently occur together, posing a significant health challenge. HIV weakens the immune system, increasing susceptibility to infections like TB. Indeed, individuals with HIV are at the greatest risk of developing TB. Traditional TB diagnosis involves culturing sputum, saliva, and mucus mix, but this process is time-consuming and often not feasible for urgent treatment needs. Additionally, sputum collection is not viable for HIV patients due to their compromised immune systems. To fill this diagnostic gap, researchers have developed a rapid, dual-detection blood test that can identify both HIV and TB simultaneously using just a small blood sample.

This breakthrough blood test, developed by researchers at Tulane University (New Orleans, LA, USA), not only identifies HIV and TB but also measures their respective viral and bacterial loads. Requiring only about 200 microliters of blood – a mere few drops – the test bypasses the need for sputum samples, making it particularly useful for HIV patients. It operates by targeting specific HIV and TB antigens present in the blood, utilizing mass spectrometry for precise measurement of viral and bacterial quantities.

A key benefit of this novel test is its ability to monitor the levels of both HIV and TB during a patient's treatment. This real-time tracking is crucial in managing immune reconstitution inflammatory syndrome (IRIS), a condition where treating one infection may exacerbate the other. The test's rapid results allow for timely adjustments in treatment strategies, enhancing patient outcomes. Such tests are especially critical in developing countries, where TB is more prevalent and access to diagnostic resources is limited. The researchers are optimistic about progressing from their initial pilot study to clinical trials and are aiming for FDA approval of the test.

“For HIV patients, their immune system is very weak, and once they are infected, they can’t confront the bacteria very well, so that’s why there is this urgent need to bring a blood-based TB tests to them,” said Tony Hu at Tulane University School of Medicine who led the research. “For the TB-infected patients, they worry, ‘Why did I get TB? Is it because I have HIV?’ So, this is a multiplex detection to cover both pathogens.”

Related Links:
Tulane University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.